In addition, our study focused on investigating the potential therapeutic efficacy of simultaneous targets of EZH2 and BTK in Burkitt’s lymphoma and exploring the underlying apoptotic pathways associated with this drug combination. This evidence concerns the gene EZH2 and Burkitt lymphoma.